VT-1953 treatment significantly reduced malignant fungating wound-associated malodor (primary endpoint) (P<0.001). Patients also reported significant improvements in lesion pain (P<0.001) and Quality ...
CAMBRIDGE, MA, UNITED STATES, January 22, 2025 /EINPresswire.com/ -- • VT-1953 treatment reduces malignant fungating wound-associated malodor over a 14 day period ...
This quarter marks Vyome's first full reporting period as a newly listed Nasdaq company. Vyome is a clinical-stage, and AI-focused company positioned to accelerate development across ...
Sign up for our newsletter to get the latest on the transformative forces shaping the global economy, delivered every Thursday.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback